A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Imeglimin in Healthy Japanese Subjects

Trial Profile

A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Imeglimin in Healthy Japanese Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 May 2017

At a glance

  • Drugs Imeglimin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Poxel
  • Most Recent Events

    • 22 May 2017 According to a Poxel media release, results from this trial were presented at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD).
    • 20 Apr 2017 According to a Poxel media release, results from this trial will be presented at the Asian Association for the Study of Diabetes, which is being held in conjunction with the 60th Annual Meeting of The Japan Diabetes Society.
    • 27 May 2015 Results published in the Poxel Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top